Recent content by danv

I suppose mostly because a different drug in the pipeline on May 15 was delayed, "Ascendis Pharma A/S (NASDAQ:ASND) announced that the FDA extended the review date for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism to Aug. 14 2024"

Hi, I'm Dan from Canada. Fairly new to swing trading and just signed up for Interactive Brokers, so learning that platform. Starting out by investing in biotech and US equity. Plan to hold stocks from 1 day to 2 months. Programming a bit with Python and backtesting swing strategies.

ASND is continuing a long slide but just received FDA Approval on May 16??? why